Trials / Unknown
UnknownNCT06117878
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK510 for Patients With Osteosarcoma and Soft Tissue Sarcoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 10 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NK510 | NK510 will be administered through intravenous infusion.once a week，for a total of six times. |
| DRUG | NK510 | NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively. |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
- First posted
- 2023-11-07
- Last updated
- 2023-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06117878. Inclusion in this directory is not an endorsement.